|
Sign In to gain access to subscriptions and/or personal tools.
|
Patent Prosecution Strategies for Stem Cell–Related Applications
Rajeev Kumar
Fernandez & Associates LLP, Menlo Park, California, Kumarrajv{at}gmail.com
Jenny J. Yeh
Fernandez & Associates LLP, Menlo Park, California
Dennis Fernandez
Fernandez & Associates LLP, Menlo Park, California
Nels Hansen
Fernandez & Associates LLP, Menlo Park, California
Stem cell research and the intellectual property derived from it, because of its potential to completely transform health care, demand an especially high level of consideration from business and patent prosecution perspectives. As with other revolutionary technologies, ordinary risks are amplified (e.g., litigation), and ordinarily irrelevant considerations may become important (e.g., heightened level of both domestic and foreign legislative risk). In the first part of this article, general strategies for patent prosecutors such as several prosecution considerations and methods for accelerating patent prosecution process are presented. In the second part, patent prosecution challenges of stem cell—related patents and possible solutions are discussed. In the final part, ethical and public policy issues particular to stem cell—related and other biotechnological inventions are summarized. (Journal of Biomolecular Screening 2007:769-774)
Key Words: stem cell • patent • prosecution
References
- 35 USC
 101-103, 2000. - Fernandez D., Achiriloaie M.: Keeping-up intellectual property lifelines for life science ventures . J High Tech L 2004;29: 30-31 .
- Isacson JP: Maximizing profits through intelligent planning and implementation . Nat Biotechnol 2000;18: 565-566 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hoffman DC: A modest proposal: toward improved access to biotechnology research tools by implementing a broad experimental use exception. Cornell L Rev 2004;993:997-1000.
- Eisenberg RS: Public research and private development: patents and technology transfer in government-sponsored research . Va L Rev 1996;1663: 1689-1695 .
- US Patent No. 4237224.
- Bastani B., Mintarno E., Fernandez D.: Technology transfer: from the lab to the shelf . Stanford BioMed Q 2003;Fall: 23 .
- Henry MR, Cho MK, Weaver MA, Merz JF: DNA patenting and licensing . Science 2002;297: 1279 .[Free Full Text]
- Restaino LG, Halpern SE, Tang EL: Patenting DNA-related inventions in the European Union, United States and Japan: a trilateral approach or a study in contrast . UCLA J L Tech 2003;2: 1-25 .
- Selinger JR: Patent Litigation Strategies Handbook. Washington, DC: BNA Books , 2000.
- US Patent and Trademark Office: Manual of Patent Examining Procedure 708.02. 8th ed. Washington, DC: US Patent and Trademark Office , 2001.
- Fuierer M.: Patenting pharmaceutical compositions, their manufacture and therapeutic use: strategic issues . IPTL 2002;4: 1-4 .
- Amgen v. Chugai, 927 F.2d 1200 (Fed Cir 1991).
- University of California v. Eli Lilly, 119 F.3d 1559, 1568 (Fed Cir 1997).
- Thomson JA, Itskovitz-Eldor J., Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al: Embryonic stem cell lines derived from human blastocyst . Science 1998;282: 1145-1147 .[Abstract/Free Full Text]
- Wilmut I., Schnieke AE, McWhir J., Kind AJ, Campbell Khs: Viable offspring derived from fetal and adult mammalian cells . Nature 1997;385: 810-813 .[CrossRef][Medline]
[Order article via Infotrieve]
- Wilson A.: Patents in the bioinformatics field: releasing the gene genie . Bio-Sci Law Rev 2002. Retrieved from http://pharmalicensing.com/features/disp/1034368662_3da73696212e0?1034858001.
- In re Warmerdam, 33 F. 3d 1354, 1360-1361 (Fed Cir 1994).
- In re Lowry, 32 F.3d 1579, 1583-1584 (Fed Cir 1994).
- US Patent and Trademark Office: Manual of Patent Examining Procedure 2106. 8th ed. Washington, DC: US Patent and Trademark Office , 2001.
- In re Alappat, 33 F.3d 1526-1544 (Fed Cir 1994).
- State Street Bank & Trust Co. v. Signature Financial Group Inc., 149 F.3d 1368, 1373 (Fed Cir 1998).
- US Patent and Trademark Office: Manual of Patent Examining Procedure 2107. 8th ed. Washington, DC: US Patent and Trademark Office , 2001.
- Chow M., Fernandez D.: Intellectual property strategy in bioinformatics and biochips. Partnering Focus 2004;9: 1-4 .[Medline]
[Order article via Infotrieve]
- Guidelines for Examination of Patent Applications under the 35 USC 112, para. 1, "Written Description" Requirement, 66 Fed. Reg. 1099, February 2003.
- Fiers v. Revel, 984 F.2d 1164, 1169-1171 (Fed Cir 1993).
- Diamond v. Chakrabarty, 447 US 303 (1980).
- US Patent and Trademark Office: Manual of Patent Examining Procedure 2105. 8th ed. Washington, DC: US Patent and Trademark Office , 2001.
- Chapman AR, Frankel MS, Garfinkel MS: Stem Cell Research and Applications Monitoring the Frontiers of Biomedical Research. Washington, DC: American Association for the Advancement of Science , 1999:405-416.
- Nash D.: Recommended response for human cloning patent application. IDEA 2002;42:279-312.
- Chambers J.: Patent eligibility of biotechnological inventions in the United States, Europe, and Japan: how much patent policy is public policy . Geo Wash Intl L Rev 2002;223: 230 .
- Tol-O-Matic Inc. v. Proma Produkt-und Marketing Gesellschaft, 945 F.2d 1546 (Fed Cir 1991).
Journal of Biomolecular Screening, Vol. 12, No. 6,
769-774 (2007)
DOI: 10.1177/1087057107305828
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
V. S. Nirmalanandhan and G. S. Sittampalam
Stem Cells in Drug Discovery, Tissue Engineering, and Regenerative Medicine: Emerging Opportunities and Challenges
J Biomol Screen,
August 1, 2009;
14(7):
755 - 768.
[Abstract]
[PDF]
|
|
|
|
|
